| Literature DB >> 18049473 |
Michael P Manns1, Graham R Foster, Jürgen K Rockstroh, Stefan Zeuzem, Fabien Zoulim, Michael Houghton.
Abstract
Infection with the hepatitis C virus (HCV) represents an important health-care problem worldwide. The prevalence of HCV-related disease is increasing, and no vaccine is yet available. Since the identification of HCV as the causative agent of non-A, non-B hepatitis, treatment has progressed rapidly, but morbidity and mortality rates are still predicted to rise. Novel, more efficacious and tolerable therapies are urgently needed, and a greater understanding of the viral life cycle has led to an increase in the number of possible targets for antiviral intervention. Here we review the specific challenges posed by HCV, and recent developments in the design of vaccines and novel antiviral agents.Entities:
Mesh:
Substances:
Year: 2007 PMID: 18049473 DOI: 10.1038/nrd2411
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN: 1474-1776 Impact factor: 84.694